The effect of interleukin-10 immunotherapy on renal ischemia-reperfusion injury: a systematic review and meta-analysis of preclinical studies
File(s)
Published version
Author(s)
Type
Journal Article
Abstract
Renal ischemia-reperfusion is a common cause of acute kidney injury leading to significant morbidity and mortality. There are no effective treatments available in clinical practice. This meta-analysis aims to assess the effect of IL-10 immunotherapy on renal ischemia-reperfusion injury. Medline, Embase, Cochrane-library, Google Scholar and clinicaltrials.gov were searched up to 31 March 2023. Preclinical and clinical interventional studies investigating IL-10 immunotherapy for renal ischemia-reperfusion were eligible for inclusion. The primary endpoint was renal function (serum creatinine) following ischemia-reperfusion. The secondary endpoints included mitochondrial integrity, cellular proliferation, regulated cell death (TUNEL assay), expression of inflammatory cytokines (TNF-α, IL-6 and IL-1β), M1/M2 macrophage polarization, tissue integrity (tubular injury score), long-term kidney fibrosis (fibrotic area %) and adverse events (pulmonary toxicity, cardiotoxicity hepatotoxicity). The search returned 861 records. From these, 16 full texts were screened and subsequently, seven animal studies, corresponding to a population of 268 mice/rats, were included. Compared to the control treatment, IL-10 immunotherapy reduced serum creatinine more effectively within 24 h of administration (95% CI: −9.177, −5.601, I2 = 22.42%). IL-10 immunotherapy promoted mitochondrial integrity and cellular proliferation and reduced regulated cell death (95% CI: −11.000, −4.184, I2 = 74.94%). It decreased the expression of TNF-α, IL-6 and IL-1β, led to M2 polarization of the local macrophages, reduced tubular injury score (95% CI: −8.917, −5.755, I2 = 22.71%), and long-term kidney fibrosis (95% CI: −6.963, −3.438, I2 = 0%). No adverse outcomes were captured. In Conclusion, IL-10 immunotherapy safely improves outcomes in animal models of renal ischemia-reperfusion; the translational potential of IL-10 immunotherapy needs to be further investigated in clinical trials.
Date Issued
2024-06-01
Date Acceptance
2024-06-01
Citation
International Journal of Molecular Sciences, 2024, 25 (11)
ISSN
1661-6596
Publisher
MDPI AG
Journal / Book Title
International Journal of Molecular Sciences
Volume
25
Issue
11
Copyright Statement
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/)
License URL
Identifier
https://www.ncbi.nlm.nih.gov/pubmed/38892418
PII: ijms25116231
Subjects
ACUTE KIDNEY INJURY
Biochemistry & Molecular Biology
Chemistry
Chemistry, Multidisciplinary
interleukin-10
ischemia-reperfusion injury
kidney transplantation
Life Sciences & Biomedicine
Physical Sciences
Science & Technology
Publication Status
Published
Coverage Spatial
Switzerland
Article Number
6231
Date Publish Online
2024-06-05